Cellectis swings to Q3 net loss of $61.47 million
CLLS•CLLS•CLLS•CLLS•Cellectis reported a third-quarter net loss of $61.47 million, compared with a profit of $589,000 a year earlier, as revenue fell 89% to $3.76 million. It had $149 million in cash, cash equivalents and term deposits at September 30, with runway into the second half of 2028 contingent on restructuring.
Cellectis swung to a third-quarter net loss of $61.47 million from a year-earlier profit of $589,000, while revenue fell 89% year over year to $3.76 million. Cash, cash equivalents and term deposits totaled $149 million at September 30, with runway into the second half of 2028 contingent on restructuring. Planned workforce reductions could reach 70% during 2026 and 2027 as the company shifts to in vivo gene editing. Initial clinical data for .HEAL-101 remain expected in the second half of 2027, and the investigator-initiated Phase 1 trial in China is on schedule.
